Capecitabine is not a targeted drug. Targeted drugs mostly refer to drugs or their preparations that can be aimed at a specific lesion site and release or accumulate active ingredients at the target site, Capecitabine is not endowed with targeting ability, so this disease is not a targeted drug. Capecitabine is a common antineoplastic agent indicated for adjuvant chemotherapy for colon cancer, metastatic colorectal cancer, breast cancer as a single agent or in combination with chemotherapy, and advanced or metastatic gastric cancer. Side effects such as anorexia, vomiting, nausea, diarrhea, abdominal pain, fatigue, drowsiness, and dermatitis are common with capecitabine. It is contraindicated in patients who are allergic to the components of this drug, who have previously had a severe, unintended reaction to fluorouracil, who are allergic to fluoropyrimidine, who have a complete lack of dihydropyrimidine dehydrogenase activity, and who have severe renal impairment. It must not be used with other analogs such as solifidine. Capecitabine must be used only under the guidance of a specialized physician, and if combination therapy is required, the contraindications to the combination of drugs should be noted.